Verve Therapeutics, Inc. - stock earnings
VERV Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -48.4 million USD | 5.1 million USD |
| 2023Q3 | -45.8 million USD | 3.1 million USD |
| 2023Q2 | -54.0 million USD | 2.1 million USD |
| 2023Q1 | -45.7 million USD | 1.4 million USD |
| 2022Q4 | -41.1 million USD | 1.0 million USD |
| 2022Q3 | -46.5 million USD | 929000 USD |
| 2022Q2 | -39.7 million USD | ? USD |
| 2022Q1 | -28.4 million USD | ? USD |
| 2021Q4 | -31.3 million USD | ? USD |
| 2021Q3 | -22.7 million USD | ? USD |
| 2021Q2 | -53.0 million USD | ? USD |
| 2021Q1 | -13.3 million USD | ? USD |
| 2020Q4 | -23.5 million USD | ? USD |
| 2020Q3 | -9.0 million USD | ? USD |
| 2020Q2 | -7.6 million USD | ? USD |
| 2020Q1 | -5.6 million USD | ? USD |
VERV Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -200.1 million USD | 11.8 million USD |
| 2022 | -157.4 million USD | 1.9 million USD |
| 2021 | -118.6 million USD | ? USD |
| 2020 | -45.5 million USD | ? USD |
| 2019 | -19.0 million USD | ? USD |
VERV
Price: $6
52 week price:
Earnings Per Share: -3.12 USD
P/E Ratio: -4.03
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 434163
Market Capitalization: 731.7 million